Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 77.8%, free cash flow grew 251.9% and total debt rose 3.15%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow BLCO
Bausch + Lomb Corporation (BLCO) EV/Sales
As of 16 October 2026, Bausch + Lomb Corporation (BLCO) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 1.8× (May 2025) to 2.6× (October 2023); the current reading is higher than 21% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | (6.89%) |
| FY2024 | 2.3× | (7.82%) |
| FY2023 | 2.5× | 22.16% |
| FY2022 | 2.0× | (16.19%) |
| FY2021 | 2.4× | 0.00% |
| FY2020 | 2.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | (0.19%) |
| Mar 2026 | 2.0× | (4.69%) |
| Dec 2025 | 2.1× | 5.11% |
| Sep 2025 | 2.0× | 5.36% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVST Envista Holdings Corporation compare | 1.4× |
| BLCO Bausch + Lomb Corporation | 2.0× |
| ALGN Align Technology, Inc. compare | 2.3× |
| ATR AptarGroup, Inc. compare | 2.3× |
| ICUI ICU Medical, Inc. compare | 2.3× |
| MMSI Merit Medical Systems, Inc. compare | 3.6× |
| TFX Teleflex Incorporated compare | 3.6× |
| STVN Stevanato Group S.p.A. compare | 3.9× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)